Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127016
Filing Date
2024-11-14
Accepted
2024-11-14 16:02:40
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20240930.htm   iXBRL 10-Q 2249239
2 EX-10.1 spro-ex10_1.htm EX-10.1 130630
3 EX-10.2 spro-ex10_2.htm EX-10.2 56395
4 EX-10.3 spro-ex10_3.htm EX-10.3 124311
5 EX-10.4 spro-ex10_4.htm EX-10.4 47713
6 EX-31.1 spro-ex31_1.htm EX-31.1 10732
7 EX-31.2 spro-ex31_2.htm EX-31.2 10879
8 EX-32 spro-ex32.htm EX-32 8705
9 GRAPHIC img175229707_0.jpg GRAPHIC 20001
  Complete submission text file 0000950170-24-127016.txt   8456053

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spro-20240930.xsd EX-101.SCH 1321107
64 EXTRACTED XBRL INSTANCE DOCUMENT spro-20240930_htm.xml XML 1069419
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 241461625
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)